This Phase II randomized study is to determine the efficacy of split-course thoracic radiotherapy combined with nab-paclitaxel plus nedaplatin for local advanced non-small cell lung cancer with severe impairment of baseline pulmonary function.~Patients received four cycles of weekly nab-paclitaxel(50mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, or nab-paclitaxel(30mg/㎡) and nedaplatin(10mg/㎡) twice every week, concurrent with split-course thoracic radiotherapy of 30 Gy/6 fractions and 40 Gy/8 fractions administered in the first and second courses, respectively, with one-month break. The primary end point is progression-free survival, which is the time that passes from the first day of radiotherapy to the date at which disease progresses. Progression-free survival will be calculated using the Kaplan-Meier method.Toxicities will be graded according to CTCAE v. 4.0.
This Phase II randomized study is to determine the efficacy of split-course thoracic radiotherapy combined with nab-paclitaxel plus nedaplatin for local advanced non-small cell lung cancer with severe impairment of baseline pulmonary function.